Enveric Biosciences Inc vs Roundhill NVDA WeeklyPay ETF — how do they compare? Enveric Biosciences Inc trades at $1.57 (market cap $6.20M), while Roundhill NVDA WeeklyPay ETF trades at $38.65. The key difference: Roundhill NVDA WeeklyPay ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ENVB | NVDW | |
|---|---|---|
Market Cap | $6.20M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $17.40 | $52.59 |
52-Week Low | $1.27 | $31.88 |
Enterprise Value | $1.30M | — |
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.56, up 1.3% on the day, with a bullish technical signal from moving averages and strong analyst support (75% buy ratings). The company reported four consecutive quarterly earnings beats in 2025, including a positive EPS of $0.85 in Q4, while recent news highlights progress in preclinical studies for its non-hallucinogenic psychiatric drug candidate EB-003.
Despite operational losses and negative ROE/ROA, ENVB's consistent earnings surprises and advancing pipeline present speculative growth potential. Key risks include cash burn, clinical trial outcomes, and regulatory hurdles, requiring careful risk assessment by investors.
No Aura AI signal available yet.
Trailing returns across standard periods
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →NVDW is an actively managed ETF that seeks to provide weekly distributions and returns equal to 1.2 times (120%) the calendar week performance of Nvidia (NVDA) common shares. It combines modest leverage with a high-frequency payout schedule, designed for investors who want amplified exposure to Nvidia alongside a consistent weekly income stream.
Read more on NVDW →